TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF) (“
Aleafia Health
” or the “
Company
”) is providing a corporate update regarding its outstanding listed unsecured convertible debentures (TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022 (the “
Convertible Debt
”).
The Company has initiated negotiations with debenture holders with a view of amending the Convertible Debt to achieve an outcome that is beneficial to all the Company’s stakeholders.
As negotiations are underway, the Company has opted to not make an interest payment due on December 31, 2021. Under the terms of the Convertible Debt, there is no event of default as a result of this non-payment for 30 calendar days from the interest payment due date. Moreover, by Extraordinary Resolution, or otherwise by resolution by holders of more than fifty percent (50%) of the principal amount of Convertible Debt, an event of default may be waived. There can be no assurance that the current negotiations will result in a transaction or, if a transaction is undertaken, that it will be successfully concluded in a timely manner.
For Investor & Media Relations:
1-833-879-2533
LEARN MORE:
www.AleafiaHealth.com
About Aleafia Health
:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The Company has developed an international footprint, with subsidiaries or investments in German and Australian medical cannabis companies and has products available in both markets. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners who have seen over 75,000 patients to date.
Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the medical and adult-use markets, and in select international jurisdictions.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
